Could a breast cancer drug help women with PCOS ovulate?
NCT ID NCT07706374
First seen Jul 15, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This study tests whether exemestane, a drug typically used for breast cancer, can help women with polycystic ovary syndrome (PCOS) ovulate. Participants take either a low or high dose of exemestane or a placebo for 5 to 10 days. Researchers track ovulation through blood tests and ultrasounds, and monitor side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- exemestane, an aromatase inhibitor drug
- What this could lead to
- If successful, exemestane could offer a new, short-course option to induce ovulation in women with PCOS who have trouble conceiving.
- What could go wrong
- This is an early-phase trial with only 40 participants, so results may not apply broadly. Side effects and lack of ovulation are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLY CYSTIC OVARY SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UNC Fertility
RECRUITINGRaleigh, North Carolina, 27617, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.